Esperion Therapeutics’ (ESPR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report report published on Friday morning,Benzinga reports.

A number of other equities analysts have also recently weighed in on ESPR. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective for the company. Cantor Fitzgerald started coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target for the company. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $7.30.

Esperion Therapeutics Trading Up 7.8 %

Shares of ESPR stock opened at $2.34 on Friday. Esperion Therapeutics has a 12-month low of $1.58 and a 12-month high of $3.94. The business’s 50 day moving average is $2.46 and its two-hundred day moving average is $2.18. The company has a market capitalization of $461.06 million, a P/E ratio of -3.66 and a beta of 1.03.

Institutional Investors Weigh In On Esperion Therapeutics

A number of hedge funds have recently modified their holdings of ESPR. Bank of New York Mellon Corp grew its stake in shares of Esperion Therapeutics by 3,278.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock valued at $1,271,000 after buying an additional 555,382 shares during the period. Rhumbline Advisers grew its position in Esperion Therapeutics by 6,560.6% in the second quarter. Rhumbline Advisers now owns 252,038 shares of the biopharmaceutical company’s stock worth $560,000 after acquiring an additional 248,254 shares during the period. National Bank of Canada FI increased its stake in Esperion Therapeutics by 115.9% during the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,225 shares during the last quarter. American Century Companies Inc. purchased a new stake in Esperion Therapeutics in the second quarter valued at $50,000. Finally, BOKF NA acquired a new position in shares of Esperion Therapeutics in the 2nd quarter valued at $26,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.